Matthew Wasserman (Matt Wasserman, Matt D Wasserman, M Wasserman)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 11

Top Topics

Randomized Controlled Trial

Klebsiella Pneumoniae

Top Venues

Expert review of vaccines

Human vaccines & immunotherapeutics

Infectious diseases and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Johnna E Perdrizet, Raymond A Farkouh, Emily K Horn, Kyla Hayford, Heather L Sings, Matthew Wasserman
The broader impacts of otitis media and sequelae for informing economic evaluations of pneumococcal conjugate vaccines. Expert review of vaccines 21 (4) (2022)
Juan Manuel Reyes-Sanchez, Jorge LaRotta, Gamboa N Castaño, Mark A Fletcher, Matthew Wasserman, Johnna E Perdrizet, Rodrigo Sini de Almeida
Letter to the editor regarding "Budget impact analysis of pneumococcal conjugate vaccines in Colombia". Expert review of pharmacoeconomics & outcomes research (2021)
Canna Jagdish Ghia, Emily K Horn, Gautam Rambhad, Johnna E Perdrizet, Ramaa Chitale, Matthew Wasserman
Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India. Infectious diseases and therapy 10 (4) (2021)
Bruce Cm Wang, Nathorn Chaiyakunapruk, Shuiqing Zhu, Joseph B Babigumira, Wesley Furnback, Ramaa Chitale, Amgad Gamil, Kun Zhao, Matthew Wasserman
A systematic literature review of economic evaluations of pneumococcal conjugate vaccines in east and southeast Asia (2006-2019). Expert review of vaccines (2021)
Emily K Horn, Matthew Wasserman, Cassandra K Hall-Murray, Heather L Sings, Ruth Chapman, Raymond A Farkouh
Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges. Expert review of vaccines 20 (10) (2021)
Matthew Wasserman, Johnna E Perdrizet, Lindsay Grant, Kyla Hayford, Shubhra Singh, Paranjoy Saharia, Emily K Horn, Raymond A Farkouh
Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age. Infectious diseases and therapy 10 (4) (2021)
Johnna Perdrizet, Carlos Felipe S Santana, Thais Senna, Rodrigo Fernandes Alexandre, Rodrigo Sini de Almeida, Julia Spinardi, Matthew Wasserman
Reply letter to "response to article by Johnna Perdrizet et al." by Gomez and colleagues. Human vaccines & immunotherapeutics (2021)
Johnna Perdrizet, Carlos Felipe S Santana, Thais Senna, Rodrigo Fernandes Alexandre, Rodrigo Sini de Almeida, Julia Spinardi, Matthew Wasserman
Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants. Human vaccines & immunotherapeutics 17 (4) (2020)
Hye-Young Kim, Seong-Beom Park, Eun-Sil Kang, Sang-Min Lee, Hyun-Jin Kim, Matthew Wasserman
Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea. Human vaccines & immunotherapeutics 17 (3) (2020)
Kunling Shen, Matthew Wasserman, Dongdong Liu, Yong-Hong Yang, Junfeng Yang, Greg F Guzauskas, Bruce C M Wang, Betsy Hilton, Raymond Farkouh
Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China. PloS one 13 (7) (2018)
Matthew Wasserman, A Lucas, D Jones, M Wilson, B Hilton, A Vyse, H Madhava, A Brogan, M Slack, R Farkouh
Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK. Epidemiology and infection 146 (14) (2018)